• English
    • Türkçe
  • Türkçe 
    • English
    • Türkçe
  • Giriş
Öğe Göster 
  •   Açık Akademik Arşiv Ana Sayfası
  • Araştırma Çıktıları / WOS
  • Araştırma Çıktıları / WOS
  • Öğe Göster
  •   Açık Akademik Arşiv Ana Sayfası
  • Araştırma Çıktıları / WOS
  • Araştırma Çıktıları / WOS
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening

Thumbnail
Göster/Aç
Discovery of new azoles with potent activity againstCandidaspp. andCandida albicansbiofilms through virtual screening.pdf (2.199Mb)
Tarih
2020
Yazar
Karakurt, Arzu
Kart, Didem
Öztürk, Naile
Kaynak, F. Betül
Gencel, Melis
Taşkor, Gülce
Karakurt, Arzu
Saraç, Selma
Eşsiz, Şebnem
Dalkara, Sevim
Özet
Systemic candidiasis is a rampant bloodstream infection ofCandidaspp. andC. albicansis the majorpathogen isolated from infected humans. Azoles, the most common class of antifungals which sufferfrom increasing resistance, and especially intrinsically resistant non-albicans Candida(NAC) species, actby inhibiting fungal lanosterol 14a-demethylase (CYP51). In this study we identified a number of azolecompounds in 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanol/ethanone oxime ester structurethrough virtual screening using consensus scoring approach, synthesized and tested them for theirantifungal properties. We reached several hits with potent activity against azole-susceptible and azole-resistantCandidaspp. as well as biofilms ofC. albicans.5i's minimum inhibitor concentration (MIC) was0.125mg/ml againstC. albicans, 0.5mg/ml againstC. kruseiand 1mg/ml against azole-resistantC. tropicalisisolate. Considering the MIC values offluconazole against these fungi (0.5, 32 and 512mg/ml, respec-tively),5iemerged as a highly potent derivative. The minimum biofilm inhibitor concentration (MBIC) of5c,5j, and5pwere 0.5mg/ml (and5iwas 2mg/ml) againstC. albicansbiofilms, lower than that ofamphotericin B (4mg/ml), afirst-line antifungal with antibiofilm activity. In addition, the active com-pounds showed neglectable toxicity to human monocytic cell line. We further analyzed the dockingposes of the active compounds inC. albicansCYP51 (CACYP51) homology model catalytic site andidentified molecular interactions in agreement with those of known azoles with fungal CYP51s andmutagenesis studies of CACYP51. We observed the stability of CACYP51 in complex with5iin moleculardynamics simulations.©2019 Elsevier Masson SAS. All rights reserved.1. IntroductionSystemic candidiasis is a major public health issue, especiallywith immune-suppressed cases reaching high mortality rates. Themembers of the genusCandidaare the most frequently recoveredfrom human fungal infection andCandida albicans, so far, is theleading pathogen identified in nosocomial candidiasis [1]. Inaddition to increasing drug-resistant strains ofC. albicans, emer-gence of non-albicans Candidaspp. (NAC) complicate the treatmentof mycoses [2].C. tropicalisis among the NACs that show reducedsusceptibility tofirst-line antifungals reportedly leading to break-through fungemia among high-risk patients [3,4]. Also,C. kruseiisknown to be intrinsically resistant to a number of azoles includingfluconazole [5]. One of the several mechanisms of therapy-resistance is formation of biofilms, which are complex microor-ganism colonies enclosed in an exopolysaccharide matrix on bioticand non-biotic surfaces. Persistent biofilms make fungi much lesssusceptible to antifungal drugs compared to their planktonic formsfor a number of reasons [6e8]. Therefore it is essential to design*Corresponding author. Hacettepe University Faculty of Pharmacy, Departmentof Pharmaceutical Chemistry, 06100, Sihhiye, Ankara, Turkey.E-mail addresses:suat.sari@hacettepe.edu.tr,suat1039@gmail.com(S. Sari).Contents lists available atScienceDirectEuropean Journal of Medicinal Chemistryjournal homepage:http://www.elsevier.com/locate/ejmechhttps://doi.org/10.1016/j.ejmech.2019.06.0830223-5234/©2019 Elsevier Masson SAS. All rights reserved.European Journal of Medicinal Chemistry 179 (2019) 634e648

Kaynak

European Journal of Medicinal Chemistry

Sayfalar

634-648-

Bağlantı

https://hdl.handle.net/20.500.12469/2829
https://doi.org/10.1016/j.ejmech.2020.112130

Koleksiyonlar

  • Araştırma Çıktıları / PubMed [194]
  • Araştırma Çıktıları / Scopus [1565]
  • Araştırma Çıktıları / WOS [1518]
  • Biyoinformatik ve Genetik / Bioinformatics and Genetics [220]

Paylaş


DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 

Göz at

Tüm Akademik ArşivBölümler & KoleksiyonlarYayın Tarihine GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreDepartmana GöreYayıncıya GöreKHAS Yazarına GöreErişim Türüne GöreBu KoleksiyonYayın Tarihine GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreDepartmana GöreYayıncıya GöreKHAS Yazarına GöreErişim Türüne Göre

Hesabım

GirişKayıt

İstatistikler

Google Analitik İstatistiklerini Görüntüle

DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV